Setipiprant_医药中间体

基础信息

CAS	866460-33-5

产品详情

Setipiprant was initially researched by Actelion as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.However, following the discovery in 2012 that the prostaglandin D2 receptor (DP/PGD2) is expressed at high levels in the scalp of men affected by male pattern baldness, the rights to setipiprant were acquired by Kythera to develop the drug as a novel treatment for baldness. The favorable pharmacokinetics and relative lack of side effects seen in earlier clinical trials mean that fresh clinical trials for this new application can be conducted fairly quickly.

Setipiprant

产品关键词：医药中间体 / Setipiprant / 866460-33-5
产品所属分类：化工/ 化工中间体/ 医药中间体

企业介绍

上海昂阁医药科技有限公司是从事医药原料药和精细化学品的创新研究、工艺开发、自营生产为一体的现代化企业，以上海为研发基地，在湖南建有化工生产基地。公司建立了完整有效的质量控制体系,依托上海的国际化窗口和外贸平台基础，产品远销美国、英国和日本等。上海昂阁医药科技有限公司研发团队源于上海大学和上海应用技术学院，和国内多所高校建有紧密的科研合作。公司拥有多名海外留学经历的研发经理，拥有博士学位的研发人员10余名，拥有多年的科研开发经历，研发中心配备高端的精密检测仪器，成功地实现了多个产品的研发和生产。上海昂阁医药科技有限公司以上海技术中心为平台，通过自主研发，开展广泛合作，加快技术创新，推动产品品质和产业结构的优化升级，掌握核心产品和技术，力争建设成具有国际竞争力和影响力的化学企业，为您提供供医药原料药、精细化工产品以及工艺设计和工艺优化等服务。昂然傲立，阁物求真！昂阁人以精益求精的品质和丝毫不懈的激情，给您提供质的产品和贴心的服务，昂阁人期待着和您携手，期待和您共创未来。

联系方式